** Shares of drug developer Disc Medicine rise ~28.6% to $60.60, highest since March
** Co says the FDA gave positive feedback supporting the design of a trial that will evaluate its genetic disorder drug bitopertin
** Bitopertin is being developed for the treatment of Erythropoietic protoporphyria $(EPP.UK)$, a rare inherited metabolic disorder
** IRON says the drug has potential for FDA's accelerated approval based on existing data
** "Improved approval timelines and clarification of confirmatory trial design are significant positives to IRON shares," says BMO Capital Markets
** Stock up 15.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.